Lenvatinib Mesylate Intermediate CAS 15568-85-1 Maʻemaʻe >97.0% (HPLC) Hale Hana

ʻO 5-(Methoxymethylene)-2,2-Dimethyl-1,3-Dioxane-4,6-Dione (CAS:15568-85-1) he mea waena o Lenvatinib Mesylate (CAS: 857890-39-2).ʻO Lenvatinib kahi lāʻau maʻi maʻi thyroid i hoʻomohala ʻia e Eisai Corporation o Iapana (Code: E7080), nona ka mea paʻa o ka waha multi-receptor tyrosine kinase (RTK) a hiki ke kāohi i ka hana kinase o ka vascular endothelial growth factor (VEGF) Receptors VEGFR1 ( FLT1), VEGFR2 (KDR), a me VEGFR3 (FLT4).Hiki nō hoʻi iā Lenvatinib ke kāohi i ke komo ʻana o nā RTK ʻē aʻe i ka angiogenesis pathological, ka ulu ʻana o ka maʻi maʻi, a me ka piʻi ʻana o ka maʻi maʻi koe wale nō kā lākou mau hana kelepona maʻamau me ka fibroblast growth factor (FGF) receptors FGFR1, 2, 3, a me 4;ʻO ka platelet-derived growth factor receptor (PDGFR [alpha]), KIT, a me RET.[Nā hōʻike]: He kūpono ʻo Lenvatinib no ka mālama ʻana i nā maʻi o ka maʻi maʻi thyroid o ka hoʻi hou ʻana a i ʻole ke ʻano metastasis, ke ʻano holomua a me ka radioactive iodine-refractory differentiated type.Ma Pepeluali 13, 2015, ua ʻae ka US FDA i ka lāʻau anticancer Lenvatinib no ka mālama ʻana i ka maʻi maʻi thyroid.ʻO Lenvatinib kahi mea hoʻopaneʻe enzyme multi-target, hiki iā ia ke pale i ka VEGFR2 a me VEGFR3 (vascular endothelial growth factor receptor).ʻO Lenvima ka inoa kālepa o Lenvatinib.Ma Mei 20, 2015, ua ʻae ka European Medicines Agency (EMA) iā Lenvatinib no ka mālama ʻana i ka invasive, locally advanced or metastatic differentiated (papillary, follicular, Hurthle type) thyroid cancer (DTC).I ka hoʻokolokolo ʻana, ʻo ka manawa ola median no nā maʻi o ka radioactive iodine-refractory DTC i mālama ʻia me Lenvatinib he 18 mau mahina aʻo ka waiwai no nā maʻi e lawe i ka placebo he 3 mahina wale nō.